Congestive heart failure treatment of patients with refractory end-stage heart failure (Stage D): Difference between revisions
No edit summary |
No edit summary |
||
Line 24: | Line 24: | ||
'''1.''' Meticulous identification and control of fluid retention is recommended in patients with [[refractory endstage HF]]. <ref name="pmid7398185">{{cite journal |author=Brater DC, Chennavasin P, Seiwell R |title=Furosemide in patients with heart failure: shift in dose-response curves |journal=[[Clinical Pharmacology and Therapeutics]] |volume=28 |issue=2 |pages=182–6 |year=1980 |month=August |pmid=7398185 |doi= |url= |accessdate=2012-04-06}}</ref><ref name="pmid8800113">{{cite journal |author=Dormans TP, van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P |title=Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion |journal=[[Journal of the American College of Cardiology]] |volume=28 |issue=2 |pages=376–82 |year=1996 |month=August |pmid=8800113 |doi=10.1016/0735-1097(96)00161-1 |url=http://linkinghub.elsevier.com/retrieve/pii/0735-1097(96)00161-1 |accessdate=2012-04-06}}</ref><ref name="pmid9284855">{{cite journal |author=Cotter G, Weissgarten J, Metzkor E, Moshkovitz Y, Litinski I, Tavori U, Perry C, Zaidenstein R, Golik A |title=Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure |journal=[[Clinical Pharmacology and Therapeutics]] |volume=62 |issue=2 |pages=187–93 |year=1997 |month=August |pmid=9284855 |doi=10.1016/S0009-9236(97)90067-9 |url=http://dx.doi.org/10.1016/S0009-9236(97)90067-9 |accessdate=2012-04-06}}</ref><ref name="pmid16437464">{{cite journal |author=Faris R, Flather MD, Purcell H, Poole-Wilson PA, Coats AJ |title=Diuretics for heart failure |journal=[[Cochrane Database of Systematic Reviews (Online)]] |volume= |issue=1 |pages=CD003838 |year=2006 |pmid=16437464 |doi=10.1002/14651858.CD003838.pub2 |url=http://dx.doi.org/10.1002/14651858.CD003838.pub2 |accessdate=2012-04-06}}</ref><ref name="pmid16325040">{{cite journal |author=Costanzo MR, Saltzberg M, O'Sullivan J, Sobotka P |title=Early ultrafiltration in patients with decompensated heart failure and diuretic resistance |journal=[[Journal of the American College of Cardiology]] |volume=46 |issue=11 |pages=2047–51 |year=2005 |month=December |pmid=16325040 |doi=10.1016/j.jacc.2005.05.099 |url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(05)02208-4 |accessdate=2012-04-06}}</ref><ref name="pmid12932605">{{cite journal |author=Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E |title=Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD) |journal=[[Journal of the American College of Cardiology]] |volume=42 |issue=4 |pages=705–8 |year=2003 |month=August |pmid=12932605 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/S0735109703007654 |accessdate=2012-04-06}}</ref><ref name="pmid12106936">{{cite journal |author=Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Marino P, Zardini P |title=Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure |journal=[[Journal of the American College of Cardiology]] |volume=40 |issue=2 |pages=304–10 |year=2002 |month=July |pmid=12106936 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/S0735109702019654 |accessdate=2012-04-06}}</ref><ref name="pmid11853901">{{cite journal |author=Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A |title=Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials |journal=[[International Journal of Cardiology]] |volume=82 |issue=2 |pages=149–58 |year=2002 |month=February |pmid=11853901 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/S0167527301006003 |accessdate=2012-04-06}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' | '''1.''' Meticulous identification and control of fluid retention is recommended in patients with [[refractory endstage HF]]. <ref name="pmid7398185">{{cite journal |author=Brater DC, Chennavasin P, Seiwell R |title=Furosemide in patients with heart failure: shift in dose-response curves |journal=[[Clinical Pharmacology and Therapeutics]] |volume=28 |issue=2 |pages=182–6 |year=1980 |month=August |pmid=7398185 |doi= |url= |accessdate=2012-04-06}}</ref><ref name="pmid8800113">{{cite journal |author=Dormans TP, van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P |title=Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion |journal=[[Journal of the American College of Cardiology]] |volume=28 |issue=2 |pages=376–82 |year=1996 |month=August |pmid=8800113 |doi=10.1016/0735-1097(96)00161-1 |url=http://linkinghub.elsevier.com/retrieve/pii/0735-1097(96)00161-1 |accessdate=2012-04-06}}</ref><ref name="pmid9284855">{{cite journal |author=Cotter G, Weissgarten J, Metzkor E, Moshkovitz Y, Litinski I, Tavori U, Perry C, Zaidenstein R, Golik A |title=Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure |journal=[[Clinical Pharmacology and Therapeutics]] |volume=62 |issue=2 |pages=187–93 |year=1997 |month=August |pmid=9284855 |doi=10.1016/S0009-9236(97)90067-9 |url=http://dx.doi.org/10.1016/S0009-9236(97)90067-9 |accessdate=2012-04-06}}</ref><ref name="pmid16437464">{{cite journal |author=Faris R, Flather MD, Purcell H, Poole-Wilson PA, Coats AJ |title=Diuretics for heart failure |journal=[[Cochrane Database of Systematic Reviews (Online)]] |volume= |issue=1 |pages=CD003838 |year=2006 |pmid=16437464 |doi=10.1002/14651858.CD003838.pub2 |url=http://dx.doi.org/10.1002/14651858.CD003838.pub2 |accessdate=2012-04-06}}</ref><ref name="pmid16325040">{{cite journal |author=Costanzo MR, Saltzberg M, O'Sullivan J, Sobotka P |title=Early ultrafiltration in patients with decompensated heart failure and diuretic resistance |journal=[[Journal of the American College of Cardiology]] |volume=46 |issue=11 |pages=2047–51 |year=2005 |month=December |pmid=16325040 |doi=10.1016/j.jacc.2005.05.099 |url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(05)02208-4 |accessdate=2012-04-06}}</ref><ref name="pmid12932605">{{cite journal |author=Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E |title=Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD) |journal=[[Journal of the American College of Cardiology]] |volume=42 |issue=4 |pages=705–8 |year=2003 |month=August |pmid=12932605 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/S0735109703007654 |accessdate=2012-04-06}}</ref><ref name="pmid12106936">{{cite journal |author=Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Marino P, Zardini P |title=Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure |journal=[[Journal of the American College of Cardiology]] |volume=40 |issue=2 |pages=304–10 |year=2002 |month=July |pmid=12106936 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/S0735109702019654 |accessdate=2012-04-06}}</ref><ref name="pmid11853901">{{cite journal |author=Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A |title=Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials |journal=[[International Journal of Cardiology]] |volume=82 |issue=2 |pages=149–58 |year=2002 |month=February |pmid=11853901 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/S0167527301006003 |accessdate=2012-04-06}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' | ||
'''2.''' Referral for [[cardiac transplantation]] in potentially eligible patients is recommended for patients with [[refractory end-stage HF]]. ( | '''2.''' Referral for [[cardiac transplantation]] in potentially eligible patients is recommended for patients with [[refractory end-stage HF]]. <ref name="pmid16962463">{{cite journal |author=Jessup M, Banner N, Brozena S, Campana C, Costard-Jäckle A, Dengler T, Hunt S, Metra M, Rahmel A, Renlund D, Ross H, Warner Stevenson L |title=Optimal pharmacologic and non-pharmacologic management of cardiac transplant candidates: approaches to be considered prior to transplant evaluation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006 |journal=[[The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation]] |volume=25 |issue=9 |pages=1003–23 |year=2006 |month=September |pmid=16962463 |doi=10.1016/j.healun.2006.06.007 |url=http://linkinghub.elsevier.com/retrieve/pii/S1053-2498(06)00459-1 |accessdate=2012-04-06}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' | ||
'''3.''' Referral of patients with [[refractory end-stage HF]] to an [[HF]] program with expertise in the management of [[refractory HF]] is useful. (218-221) ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' | '''3.''' Referral of patients with [[refractory end-stage HF]] to an [[HF]] program with expertise in the management of [[refractory HF]] is useful. (218-221) ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' |
Revision as of 14:39, 6 April 2012
Heart failure | |
ICD-10 | I50.0 |
---|---|
ICD-9 | 428.0 |
DiseasesDB | 16209 |
MedlinePlus | 000158 |
MeSH | D006333 |
Congestive Heart Failure Microchapters |
Pathophysiology |
---|
Differentiating Congestive heart failure from other Diseases |
Diagnosis |
Treatment |
Medical Therapy: |
Surgical Therapy: |
ACC/AHA Guideline Recommendations
|
Specific Groups: |
Congestive heart failure treatment of patients with refractory end-stage heart failure (Stage D) On the Web |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Lakshmi Gopalakrishnan, M.B.B.S. [2]
Overview
ACC/AHA Guidelines- Treatment of Patients with Refractory End-Stage Heart Failure (Stage D) (DO NOT EDIT) [1][2]
“ |
Class I1. Meticulous identification and control of fluid retention is recommended in patients with refractory endstage HF. [3][4][5][6][7][8][9][10] (Level of Evidence: B) 2. Referral for cardiac transplantation in potentially eligible patients is recommended for patients with refractory end-stage HF. [11] (Level of Evidence: B) 3. Referral of patients with refractory end-stage HF to an HF program with expertise in the management of refractory HF is useful. (218-221) (Level of Evidence: A) 4. Options for end-of-life care should be discussed with the patient and family when severe symptoms in patients with refractory end-stage HF persist despite application of all recommended therapies. (Level of Evidence: C) 5. Patients with refractory end-stage HF and implantable defibrillators should receive information about the option to inactivate defibrillation. (Level of Evidence: C) Class IIa1. Consideration of an LV assist device as permanent or “destination” therapy is reasonable in highly selected patients with refractory end-stage HF and an estimated 1-year mortality over 50% with medical therapy. (222,223) (Level of Evidence: B) Class IIb1. Pulmonary artery catheter placement may be reasonable to guide therapy in patients with refractory end-stage HF and persistently severe symptoms. (217,224) (Level of Evidence: C) 2. The effectiveness of mitral valve repair or replacement is not established for severe secondary mitral regurgitation in refractory end-stage HF. (225-227) (Level of Evidence: C) 3. Continuous intravenous infusion of a positive inotropic agent may be considered for palliation of symptoms in patients with refractory end-stage HF. (228,229) (Level of Evidence: C) Class III1. Partial left ventriculectomy is not recommended in patients with non ischemic cardiomyopathy and refractory end-stage HF. (Level of Evidence: C) 2. Routine intermittent infusions of vasoactive and positive inotropic agents are not recommended for patients with refractory end-stage HF. (230,231) [12][13] (Level of Evidence: A) |
” |
Vote on and Suggest Revisions to the Current Guidelines
Guidelines Resources
- The ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult [1]
- 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation [2]
References
- ↑ 1.0 1.1 Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 (12):e154-235. DOI:10.1161/CIRCULATIONAHA.105.167586 PMID: 16160202
- ↑ 2.0 2.1 Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. (2009) 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119 (14):1977-2016. DOI:10.1161/CIRCULATIONAHA.109.192064 PMID: 19324967
- ↑ Brater DC, Chennavasin P, Seiwell R (1980). "Furosemide in patients with heart failure: shift in dose-response curves". Clinical Pharmacology and Therapeutics. 28 (2): 182–6. PMID 7398185. Unknown parameter
|month=
ignored (help);|access-date=
requires|url=
(help) - ↑ Dormans TP, van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P (1996). "Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion". Journal of the American College of Cardiology. 28 (2): 376–82. doi:10.1016/0735-1097(96)00161-1. PMID 8800113. Retrieved 2012-04-06. Unknown parameter
|month=
ignored (help) - ↑ Cotter G, Weissgarten J, Metzkor E, Moshkovitz Y, Litinski I, Tavori U, Perry C, Zaidenstein R, Golik A (1997). "Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure". Clinical Pharmacology and Therapeutics. 62 (2): 187–93. doi:10.1016/S0009-9236(97)90067-9. PMID 9284855. Retrieved 2012-04-06. Unknown parameter
|month=
ignored (help) - ↑ Faris R, Flather MD, Purcell H, Poole-Wilson PA, Coats AJ (2006). "Diuretics for heart failure". Cochrane Database of Systematic Reviews (Online) (1): CD003838. doi:10.1002/14651858.CD003838.pub2. PMID 16437464. Retrieved 2012-04-06.
- ↑ Costanzo MR, Saltzberg M, O'Sullivan J, Sobotka P (2005). "Early ultrafiltration in patients with decompensated heart failure and diuretic resistance". Journal of the American College of Cardiology. 46 (11): 2047–51. doi:10.1016/j.jacc.2005.05.099. PMID 16325040. Retrieved 2012-04-06. Unknown parameter
|month=
ignored (help) - ↑ Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E (2003). "Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD)". Journal of the American College of Cardiology. 42 (4): 705–8. PMID 12932605. Retrieved 2012-04-06. Unknown parameter
|month=
ignored (help) - ↑ Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Marino P, Zardini P (2002). "Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure". Journal of the American College of Cardiology. 40 (2): 304–10. PMID 12106936. Retrieved 2012-04-06. Unknown parameter
|month=
ignored (help) - ↑ Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A (2002). "Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials". International Journal of Cardiology. 82 (2): 149–58. PMID 11853901. Retrieved 2012-04-06. Unknown parameter
|month=
ignored (help) - ↑ Jessup M, Banner N, Brozena S, Campana C, Costard-Jäckle A, Dengler T, Hunt S, Metra M, Rahmel A, Renlund D, Ross H, Warner Stevenson L (2006). "Optimal pharmacologic and non-pharmacologic management of cardiac transplant candidates: approaches to be considered prior to transplant evaluation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006". The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation. 25 (9): 1003–23. doi:10.1016/j.healun.2006.06.007. PMID 16962463. Retrieved 2012-04-06. Unknown parameter
|month=
ignored (help) - ↑ Krell MJ, Kline EM, Bates ER, Hodgson JM, Dilworth LR, Laufer N et al. (1986) Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 112 (4):787-91. PMID: 3766379
- ↑ Oliva F, Latini R, Politi A, Staszewsky L, Maggioni AP, Nicolis E et al. (1999) Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J 138 (2 Pt 1):247-53. PMID: 10426835